Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 10/20 | 0.46 |
| ▸ | SELL | P14151 | 9/20 | 0.46 |
| ▸ | TLR4 | O00206 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15370423 | 1.00 | SELP (0.46) | SELPSELLTLR4AKT1CD44 | |
| SCHEMBL29944201 | 1.00 | SELP (0.46) | SELPSELLTLR4AKT1CD44 | |
| SCHEMBL31117388 | 1.00 | SELP (0.46) | SELPSELLTLR4AKT1CD44 | |
| SCHEMBL29721437 | 1.00 | SELP (0.46) | SELPSELLTLR4AKT1CD44 | |
| SCHEMBL28875524 | 1.00 | SELP (0.46) | SELPSELLTLR4AKT1CD44 | |
| SCHEMBL30424916 | 1.00 | SELP (0.46) | SELPSELLTLR4AKT1CD44 | |
| SCHEMBL17763713 | 1.00 | SELP (0.46) | SELPSELLTLR4AKT1CD44 | |
| SCHEMBL17907881 | 1.00 | SELP (0.46) | SELPSELLTLR4AKT1CD44 | |
| SCHEMBL22343497 | 1.00 | SELP (0.46) | SELPSELLTLR4AKT1CD44 | |
| SCHEMBL26742858 | 1.00 | SELP (0.46) | SELPSELLTLR4AKT1CD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104125821-A | Aqueous hair and skin cleaning compositions comprising biotensides | EVONIK INDUSTRIES AG | 2014-10-29 | — | — | CN | claimed |
| EP-4392522-B1 | A CONCENTRATED CLEANING COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2026-02-18 | — | — | EP | disclosed |
| EP-4661879-A1 | RHAMNOLIPIDS FOR WOUND HEALING | Stepan Company (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250352566-A1 | RHAMNOLIPIDS FOR WOUND HEALING | STEPAN CO (US) | 2025-11-20 | — | — | US | disclosed |
| EP-3245293-B1 | PRODUCTION OF RHAMNOLIPID COMPOSITIONS | STEPAN CO (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025228618-A1 | A PERSONAL CARE COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2025-11-06 | — | — | WO | disclosed |
| EP-4204505-B1 | POLISHING COMPOSITIONS AND METHODS OF USING THE SAME | FUJIFILM ELECTRONIC MAT USA INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12410383-B2 | Process of making a treatment composition that includes a plant rosin material and related premix compositions | THE PROCTER & GAMBLE COMPANY (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4598502-A1 | METHOD AND COMPOSITION FOR CONTROLLING ACNE USING RHAMNOLIPIDS | Stepan Company (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598632-A1 | ORAL CARE COMPOSITIONS CONTAINING RHAMNOLIPIDS | Stepan Company (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20130310330-A1 | METHOD FOR TREATING OBESITY | LEIGHTON, ANTON | 2013-11-21 | — | — | US | disclosed |
| US-20130296461-A1 | AQUEOUS COATINGS AND PAINTS INCORPORATING ONE OR MORE ANTIMICROBIAL BIOSURFACTANTS AND METHODS FOR USING SAME | RHODIA OPERATIONS (FR) | 2013-11-07 | — | — | US | disclosed |
| US-20130296461-A1 | AQUEOUS COATINGS AND PAINTS INCORPORATING ONE OR MORE ANTIMICROBIAL BIOSURFACTANTS AND METHODS FOR USING SAME | RHODIA OPERATIONS (FR) | 2013-11-07 | — | — | US | disclosed |
| US-20120322751-A1 | USE OF RHAMNOLIPIDS AS A DRUG OF CHOICE IN THE CASE OF NUCLEAR DISASTERS IN THE TREATMENT OF THE COMBINATION RADIATION INJURIES AND ILLNESSES IN HUMANS AND ANIMALS | PILJAC GORAN (HR) | 2012-12-20 | — | — | US | disclosed |
| EP-2410039-A1 | Rhamnolipids with improved cleaning | Unilever PLC (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20110257115-A1 | METHOD FOR TREATING RHINITIS AND SINUSITIS BY RHAMNOLIPIDS | LEIGHTON, ANTON | 2011-10-20 | — | — | US | disclosed |
| US-20110123623-A1 | RHAMNOLIPID MECHANISM | DESANTO KEITH | 2011-05-26 | — | — | US | disclosed |
| US-20090220603-A1 | USE OF RHAMNOLIPIDS IN WOUND HEALING, TREATING BURN SHOCK, ATHEROSCLEROSIS, ORGAN TRANSPLANTS, DEPRESSION, SCHIZOPHRENIA AND COSMETICS | PILJAC TATJANA | 2009-09-03 | — | — | US | disclosed |
| US-7262171-B1 | Use of rhamnolipids in wound healing, treating burn shock, atherosclerosis, organ transplants, depression, schizophrenia and cosmetics | PARADIGM BIOMEDICAL, INC. | 2007-08-28 | — | — | US | disclosed |
| US-20070155678-A1 | Use of rhamnolipids in wound healing, treating burn shock, atherosclerosis, organ transplants, depression, schizophrenia and cosmetics | PILJAC TATJANA | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257115-A1 | METHOD FOR TREATING RHINITIS AND SINUSITIS BY RHAMNOLIPIDS | CMA1, HRH2, LIPA | SELP 2419/4885SELL 700/4885TLR4 1221/4885 |
| US-20130310330-A1 | METHOD FOR TREATING OBESITY | FABP4, LIPA, LIPC | SELP 2684/4885SELL 2842/4885TLR4 1216/4885 |
| US-20070155678-A1 | Use of rhamnolipids in wound healing, treating burn shock, atherosclerosis, organ transplants, depression, schizophrenia and cosmetics | LIPG, LRAT, LIPA | SELP 849/4885SELL 669/4885TLR4 2192/4885 |
| US-20090220603-A1 | USE OF RHAMNOLIPIDS IN WOUND HEALING, TREATING BURN SHOCK, ATHEROSCLEROSIS, ORGAN TRANSPLANTS, DEPRESSION, SCHIZOPHRENIA AND COSMETICS | LIPG, LRAT, LIPA | SELP 849/4885SELL 669/4885TLR4 2192/4885 |
| US-20250352566-A1 | RHAMNOLIPIDS FOR WOUND HEALING | LPCAT3, LRAT, MBOAT7 | SELP 2044/4885SELL 2391/4885TLR4 2007/4885 |
| US-20110123623-A1 | RHAMNOLIPID MECHANISM | CUTA, LRAT, DDOST | SELP 680/4885SELL 551/4885TLR4 2132/4885 |
| US-20120322751-A1 | USE OF RHAMNOLIPIDS AS A DRUG OF CHOICE IN THE CASE OF NUCLEAR DISASTERS IN THE TREATMENT OF THE COMBINATION RADIATION INJURIES AND ILLNESSES IN HUMANS AND ANIMALS | ELANE, MRE11, FCGR1A | SELP 190/4885SELL 60/4885TLR4 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.